Diabetes

The AJMC^® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.

Latest News

Woman laying on bed with mobile phone, using medical app | Prostock-studio - stock.adobe.com

Mobile Text Messages Improve Diabetes, Heart Risk Control

By Pearl Steinzor

September 2nd 2025

Weekly mobile messages improved blood sugar, blood pressure, and heart health risk management in patients with type 2 diabetes (T2D), a study finds.

CGM-habrovich-stock.adobe.com

Global Gaps in Diabetes Technology, Insulin Linked to Poor Outcomes

By Pearl Steinzor

August 27th 2025

Woman with vision problem | Image credit: Jo Panuwat D - stock.adobe.com

Gaps Exist in Diabetic Retinopathy Screening Knowledge Among Providers, Study Finds

By Pearl Steinzor

August 26th 2025

heart - inthasone - stock.adobe.com

METS-IR Predicts Cardiovascular Risk in Type 2 Diabetes

By Pearl Steinzor

August 22nd 2025

eye health in a clinical setting-Microgen-stock.adobe.com

Semaglutide, Tirzepatide Linked to Small Increase in Eye Disorder Risk

By Pearl Steinzor

August 18th 2025

Advancing Care in Type 2 Diabetes and Obesity: A Coordinated, Guideline-Driven Approach

Understand how recent advances in GLP-1 receptor agonists and other therapies are transforming the treatment of type 2 diabetes and obesity through a shift of reactive to proactive care that addresses root causes of cardiometabolic disease.

AJMC Peer Exchange geometric background

Continuing Medical Education

September 5th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 5th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Phase 3 Trials Show Lilly’s Tirzepatide Reduces A1C, Body Weight Among Patients With T2D

February 18th 2021

Phase 3 Trials Show Lilly’s Tirzepatide Reduces A1C, Body Weight Among Patients With T2D

The SURPASS program, which consists in part of SURPASS-3 and SURPASS-5, is testing the efficacy and safety of tirzepatide, a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

Trial Finds Semaglutide With Lifestyle Intervention Reduces Body Weight by Nearly 15%

February 10th 2021

Trial Finds Semaglutide With Lifestyle Intervention Reduces Body Weight by Nearly 15%

In the placebo-controlled trial, 86% of participants who received semaglutide attained at least a 5% reduction in total body weight.

Prediabetes May Not Necessitate Diabetes Development in Older Adults

February 8th 2021

Prediabetes May Not Necessitate Diabetes Development in Older Adults

Prediabetes may not be a robust diagnostic biomarker for predicting future diabetes development in older adults.

GD May Increase Heart Disease Risk Despite Achieving Normal Blood Glucose Levels

February 3rd 2021

GD May Increase Heart Disease Risk Despite Achieving Normal Blood Glucose Levels

Results of a prospective cohort study suggest history of gestational diabetes (GD) may promote development of atherosclerotic plaque, potentially increasing the risk of future heart disease among women, even in the absence of hyperglycemia.

Recognizing the Role of Systemic Racism in Diabetes Disparities

February 2nd 2021

Recognizing the Role of Systemic Racism in Diabetes Disparities

There needs to be broad acceptance of the role systemic racism plays in social determinants of health in order to improve metabolic outcomes among minority populations in the United States.

Heart

January 27th 2021

Insulin Resistance, Diabetes Strongly Linked With Premature CHD Among Women

A prospective cohort study found that diabetes and insulin resistance were the strongest risk factors for premature onset of coronary heart disease (CHD) among American women. Results were published in JAMA Cardiology.

Metabolic Surgery Superior to Drug Therapy at Controlling Type 2 Diabetes, Study Says

January 25th 2021

Metabolic Surgery Superior to Drug Therapy at Controlling Type 2 Diabetes, Study Says

Metabolic surgery is more effective than conventional medical therapy in the long-term control of type 2 diabetes (T2D), according to results of a 10-year follow-up study of a randomized controlled trial published in The Lancet.

Study Weighs Perceived Benefits, Costs of RDM Adoption for Diabetes Management

January 20th 2021

Study Weighs Perceived Benefits, Costs of RDM Adoption for Diabetes Management

Results of a vignette-based survey study indicate patients with diabetes require greater health benefits to adopt more intrusive remote digital monitoring (RDM), food monitoring, and real-time feedback by a health care professional.

Trial Finds Bimagrumab Aids Weight Loss in Patients With T2D, Obesity

January 18th 2021

Trial Finds Bimagrumab Aids Weight Loss in Patients With T2D, Obesity

Results of a phase 2 trial showed that an activin type II receptor blockade, achieved via bimagrumab, led to significant loss of fat mass, gain in lean mass, and metabolic improvements among patients with type 2 diabetes (T2D) and overweight or obesity.

Diabetes definition page

January 13th 2021

Black Americans With T1D, COVID-19 Have Increased Risk of Hospitalization for DKA

Non-Hispanic Black individuals with type 1 diabetes and coronavirus disease 2019 infections may be more likely to be hospitalized for diabetic ketoacidosis (DKA) compared with non-Hispanic White patients.

ADA Survey Highlights COVID-19’s Impact on Americans With Diabetes

January 11th 2021

ADA Survey Highlights COVID-19’s Impact on Americans With Diabetes

A new American Diabetes Association (ADA) survey highlights how the coronavirus disease 2019 (COVID-19) pandemic took a toll on the population with diabetes, which is one of the most prevalent preexisting conditions in America.

January 11th 2021

Jardiance 1 Step Closer to FDA Approval for Use in Heart Failure

The FDA today accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for Jardiance (empagliflozin), the sodium glucose co-transporter 2 inhibitor being investigated for use in patients with heart failure.

Michael Snyder, PhD

January 7th 2021

Michael Snyder Discusses How Precision Health Measurements Can Impact Diabetes Detection and Management

Michael Snyder, PhD, professor and chair of genetics at the Stanford University School of Medicine, discusses the ways in which precision health measurements can aid physicians in detecting and better managing diabetes.

Improved Periconception A1C Linked to Reduction in Adverse Pregnancy Outcomes

January 4th 2021

Improved Periconception A1C Linked to Reduction in Adverse Pregnancy Outcomes

A reduction in glycated hemoglobin (A1C) may result in improved perinatal and maternal outcomes among women with prepregnancy diabetes, according to results of a cohort study published in JAMA Network Open.

Machine Learning Predicts Incidence of Gestational Diabetes

December 30th 2020

Machine Learning Predicts Incidence of Gestational Diabetes

Using advanced machine learning models, researchers in China were able to accurately predict incidence of gestational diabetes among pregnant women during their first trimester.

Top 5 Most-Read Diabetes Articles of 2020

December 23rd 2020

Top 5 Most-Read Diabetes Articles of 2020

Advancements in coverage for diabetes technology and improvement in diabetic retinopathy screening rates appear on this year’s list of most-read diabetes articles.

Review Details Relationship Between Frailty, Diabetes in Older Populations

December 22nd 2020

Review Details Relationship Between Frailty, Diabetes in Older Populations

The identification and assessment of frailty, defined as a state of increased vulnerability to adverse health outcomes resulting from loss of physiological reserve, should become a routine aspect of diabetes care, authors of a systematic review and meta-analysis published in The Lancet Health Longevity argued.

Empagliflozin Linked to 20% Drop in Care Costs for T2D, CVD

December 15th 2020

Empagliflozin Linked to 20% Drop in Care Costs for T2D, CVD

An outcomes-based agreement conducted by Boehringer Ingelheim and Highmark found that use of Jardiance (empagliflozin) among adults with type 2 diabetes (T2D) and known cardiovascular disease (CVD) was associated with a total cost of care savings of over 20%.

Poxel's PXL770 Shows Promise in Patients With NASH, T2D

December 14th 2020

Poxel's PXL770 Shows Promise in Patients With NASH, T2D

Results from a phase 2 trial show PXL770 yielded consistently greater responses in high-risk patients with comorbid nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2D) compared with placebo.

Experts Discuss Benefits, Limitations of Pediatric Obesity Interventions

December 7th 2020

Experts Discuss Benefits, Limitations of Pediatric Obesity Interventions

During a session at the at the 18th annual World Congress Insulin Resistance, Diabetes & Cardiovascular Disease presented by the Metabolic Institute of America, experts outlined the benefits and limitations of pharmacological, surgical, and lifestyle interventions for pediatric patients with obesity.

Dr Paul Zimmet Outlines COVID-19, Diabetes Challenges and Lessons Learned From the Pandemic

December 4th 2020

Dr Paul Zimmet Outlines COVID-19, Diabetes Challenges and Lessons Learned From the Pandemic

In a session at the 18th annual World Congress Insulin Resistance, Diabetes & Cardiovascular Disease presented by the Metabolic Institute of America, experts discussed challenges faced by patients with diabetes in the wake of the coronavirus disease 2019 (COVID-19) pandemic and lessons learned from the crisis.

Kentucky Telemedicine Program Increases Diabetic Retinopathy Screening Rates

November 28th 2020

Kentucky Telemedicine Program Increases Diabetic Retinopathy Screening Rates

Large telemedicine diabetic retinopathy screening networks based in federally designated safety-net clinics may be able to increase screening access and compliance among otherwise underscreened populations.

Scale wrapped with measuring tape

November 18th 2020

NDPS Data Show Minor Weight Loss Can Almost Halve T2D Risk

For individuals currently in high-risk glycemic categories, losing 2 to 3 kg (4.5-6.5 lb) in combination with increased physical activity over 2 years nearly halved the risk of developing type 2 diabetes (T2D).

Individual hold heart

November 16th 2020

Most Patients With T2D Classified as "High Risk" for Fatal Heart Attack, Stroke

Half of patients with type 2 diabetes (T2D) exhibit very high cardiovascular risk while the majority are at a high risk of fatal heart attack or stroke, according to new research published in the European Journal of Preventive Cardiology.

Paper cutouts of people of various colors

November 14th 2020

Reducing Racial, Ethnic Disparities in Diabetes Prevalence Requires a Multifaceted Approach

Skylar Jeremias

Lowering the higher rates of diabetes seen among racial and ethnic minorities requires solutions to address all of the major factors that contribute to diabetes prevalence.

Race Impacts DME Treatment Efficacy, Study Finds

November 10th 2020

Race Impacts DME Treatment Efficacy, Study Finds

Black individuals with diabetic macular edema (DME) exhibited a significantly lower likelihood of visual acuity improvement following intravitreal bevacizumab treatment compared with White and Hispanic patients.

Two-Year Data Show Combined Efficacy of GLP-1 RAs, SGLT2s for T2D

November 6th 2020

Two-Year Data Show Combined Efficacy of GLP-1 RAs, SGLT2s for T2D

New data show combining glucagon-like peptide-1 receptor agonist (GLP-1 RA) exenatide plus sodium–glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin remains effective after 2 years for type 2 diabetes (T2D) uncontrolled with metformin.

What We’re Reading: J&J Loses Appeal; Opioid Settlement in the Works; Diabetes Prevention Results Released

November 4th 2020

What We’re Reading: J&J Loses Appeal; Opioid Settlement in the Works; Diabetes Prevention Results Released

A decision was upheld that Johnson & Johnson (J&J) must pay a $2.1-billion fine from a 2018 court decision; 3 major drug distributors face up to $18 billion in opioid-related fines; a new diabetes prevention platform may assist in symptom prevention.

November 4th 2020

Differences in Spending for Diabetes and Multiple Chronic Conditions in Michigan Medicare Beneficiaries

John M. Clements, PhD Neli P. Ragina, PhD Jordan Killingsworth, BS Thomas G. Weiss, BS S. Akbar Husain, BS Mariam Zunnu Rain, BS Kellie M. Clark, BS Spandana Alla, BS Michelle G. Jin, BS

Diabetes and multiple chronic conditions increase overall Medicare spending, but spending increases even more in minority beneficiaries compared with White beneficiaries with similar comorbidity combinations.

CMS Proposes New Rules for CGM Coverage Among Medicare Beneficiaries

October 29th 2020

CMS Proposes New Rules for CGM Coverage Among Medicare Beneficiaries

This week, CMS proposed changes to the Medicare Durable Medical Equipment Prosthetics, Orthic Devices and Supplies (DMEPOS) coverage and payment policies which would expand Medicare coverage for continuous glucose monitors (CGMs).

...

10 11 12 13 14 15 16 17 18

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions